Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study

Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men

Ulf Risérus, Dennis L. Sprecher, Tony G. Johnson et al. · Diabetes · 2007 · 319 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor γ-activating Properties

Mauricio J. Reginato, Shannon T. Bailey, Samuel L. Krakow et al. · Journal of Biological Chemistry · 1998 · 182 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

IDF Diabetes Atlas : sixth edition

Florencia Aguiree, Alex Brown, Nam Ho Cho et al. · Deakin Research Online (Deakin University) · 2013 · 173 citations

Public Health, Demography, Population Health Sciences +8

Saroglitazar, a novel PPAR<i>α</i>/<i>γ</i> agonist with predominant PPAR<i>α</i> activity, shows lipid‐lowering and insulin‐sensitizing effects in preclinical models

Mukul R. Jain, Suresh Giri, Chitrang Trivedi et al. · Pharmacology Research & Perspectives · 2015 · 95 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

The PPAR<i>α</i>/<i>γ</i> dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats

Pingping Li, Yue-teng Chen, Zhiqiang Ning et al. · British Journal of Pharmacology · 2006 · 70 citations · Full text

Medicine, Endocrinology, Pharmacology +17